Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study

Trial Profile

A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Zilucoplan (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Sponsors Ra Pharmaceuticals
  • Most Recent Events

    • 27 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Feb 2018 According to a Ra Pharmaceuticals media release, a total of 21 patients completed the initial 12-week dosing period and 16 of those patients (or 76%) are continuing treatment with RA101495 SC in the this study (8 naive patients and 8 switch patients, including all 3 inadequate responders).
    • 24 Nov 2017 This trial was discontinued in Denmark, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top